Features | Partner Sites | Information | LinkXpress
Sign In
AB Sciex
SEEGENE
RANDOX LABORATORIES

Test Identifies Risk of Developing Lymphoma

By Labmedica International staff writers
Posted on 17 Feb 2014
Image: Micrograph of large B-cell lymphoma from a fine needle aspirate of a lymph node (Photo courtesy of Nephron).
Image: Micrograph of large B-cell lymphoma from a fine needle aspirate of a lymph node (Photo courtesy of Nephron).
The immune system is responsible for eliminating potentially cancerous immune B-cells in their early stages, before they developed into B-cell lymphomas, also known as non-Hodgkin's lymphomas.

Immune cells undergo spontaneous changes on a daily basis that could lead to cancers if not for the diligent surveillance of the immune system and this immune surveillance accounts for the surprising rarity of B-cell lymphomas in the population, given how often these spontaneous changes occur.

Scientists at Walter and Eliza Hall Institute (Melbourne, Australia) discovered that the loss of function of the tumor suppressor gene PR Domain Containing 1, with ZNF Domain (PRDM1), also known as B-Lymphocyte-Induced Maturation Protein (BLIMP1) or deregulated expression of the oncogene B-Cell CLL/Lymphoma 6 (BCL6), occurs in a large proportion of diffuse large B-cell lymphoma (DLBCL) cases.

Targeted mutation of either gene in a rodent model leads to only slow and infrequent development of malignant lymphoma and despite frequent mutation of BCL6 in activated B- cells of healthy individuals, lymphoma development is rare. The scientists found that T-cells prevent the development of overt lymphoma, and impairment of T-cell control results in rapid development of DLBCL-like disease, which can be eradicated by polyclonal cluster of differentiation 8 (CD8+) T-cells in a T-cell receptor, CD28-dependent and Fas ligand-dependent manner.

David Tarlinton, PhD, a coauthor of the study, said, “In the majority of patients, the first sign that something is wrong is finding an established tumor, which in many cases is difficult to treat. Now that we know B-cell lymphoma is suppressed by the immune system, we could use this information to develop a diagnostic test that identifies people in early stages of this disease, before tumors develop and they progress to cancer. There are already therapies that could remove these 'aberrant' B-cells in at-risk patients, so once a test is developed it can be rapidly moved towards clinical use.” The study was published on February 2, 2014, in the journal Nature Medicine.

Related Links:

Walter and Eliza Hall Institute
 


GREINER-BIO-ONE
ADVANCED INSTRUMENTS
PURITAN MEDICAL
BioConferenceLive

Channels

Clinical Chemistry

view channel
Image: The ICON 25 hCG point-of-care pregnancy test (Photo courtesy of Beckman Coulter).

Pregnancy Tests Evaluated During Early Gravidity

The predominant hormone human chorionic gonadotropin (hCG) variant in urine, hCG β core fragment (hCGβcf), has been demonstrated to cause false-negative results in qualitative point-of-care (POC) hCG devices.... Read more

Genetic Tests

view channel
Image: The Quant-iT PicoGreen dsDNA Assay Kit (Photo courtesy of Invitrogen).

Blood Test Provides Rapid Method of Detecting Solid Cancers

Circulating tumor DNA (ctDNA) is a promising biomarker for noninvasive assessment of cancer burden, but existing detection methods have insufficient sensitivity or patient coverage for broad clinical applicability.... Read more

Hematology

view channel

Blood Donations Screened for Viruses Using Multiplex Assay

A global healthcare company was chosen to partner the Japanese Red Cross (JRC; Tokyo, Japan) for nucleic acid screening of the nation's blood supply. Under the terms of the 7-year agreement, the healthcare company, Grifols (Barcelona, Spain) will provide the JRC with its newest automation platform, the Procleix Panther... Read more

Pathology

view channel
Image: Micrograph showing prostatic acinar adenocarcinoma, the most common form of prostate cancer (Photo courtesy of Zephron).

New Test Could Accurately Predict Prostate Cancer Recurrence

A test based on genetic signature and tumor oxygen levels, which boost the test’s accuracy, can predict whether a man is at high risk of prostate cancer recurrence. Prostate cancer is the most common... Read more

Industry News

view channel

Roche and Hitachi Renew Alliance in Diagnostics

Roche (Basel, Switzerland) and Hitachi (Tokyo, Japan) have renewed their alliance in the diagnostics business by 10-years for the joint development and manufacture of the next generation of instruments and workflow automation solutions for medical laboratories. The renewed alliance marks a significant milestone towards... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.